Ozempic (semaglutide) tablets are now a real, FDA-labeled product—not a rumor, not a telehealth rebrand, not a compounding workaround. The practical question for clinicians and patients is boring in the best way: what does the label actually say, how do you dose it, and what changes (or doesn’t) in a market that has been running on supply anxiety for two straight years?
This week’s news hook is a Novo Nordisk announcement that Ozempic tablets would be available in the U.S. starting May 4, 2026, in 1.5 mg, 4 mg, and 9 mg strengths (PR Newswire). But the sturdier source is the FDA-approved prescribing information, which lays out the initiation phase, titration, switching rules, and boxed warning in plain text (FDA label (PDF)).
Below is the label-first reality check—and what it means for the peptide industry’s most sensitive fault line: the boundary between FDA-approved peptide medicines and the gray-market narratives that flourish when demand outpaces supply.
What Ozempic tablets are (and what they aren’t)
Ozempic tablets are oral semaglutide, a GLP-1 receptor agonist peptide, in FDA-labeled tablet strengths of 1.5 mg, 4 mg, and 9 mg (FDA label (PDF)). They sit alongside semaglutide injections (Ozempic) and earlier oral semaglutide tablets marketed as Rybelsus.
Two points that matter in practice:
- “Oral GLP-1” doesn’t automatically mean “the weight-loss pill.” This label is for type 2 diabetes glycemic control and cardiovascular-risk language described in the product labeling and company messaging (PR Newswire).
- Brand names can hide a formulation story. The FDA label explicitly distinguishes RYBELSUS tablets (3/7/14 mg) from OZEMPIC tablets (1.5/4/9 mg) (FDA label (PDF)).
Dosing: the initiation phase is the headline
If you only remember one label detail, make it this: the starting dose is deliberately not for glycemic control.
The Ozempic tablets schedule in the FDA label is:
- Days 1–30: 1.5 mg once daily—“not effective for glycemic control.”
- Days 31–60: increase to 4 mg once daily.
- Day 61+: maintain 4 mg if adequate; increase to 9 mg if additional glycemic control is needed.
That language and timeline are stated directly in the prescribing information (FDA label (PDF)).
Why does this matter beyond pharmacology? Because people living in shortage economics often want the strongest dose immediately. The label is explicit: titration isn’t a suggestion; it’s the safety ramp designed to reduce GI adverse reactions (FDA label (PDF)).
Switching rules: oral-to-oral and injection-to-oral
The FDA label includes a dedicated switching section that answers the two most common practical questions: “Can I switch between the oral products?” and “Can I switch from the injection?” (FDA label (PDF)).
Switching between Rybelsus and Ozempic tablets
- Don’t switch during Days 1–30 (the initiation phase).
- After the initiation phase, the label provides equivalencies: 7 mg Rybelsus ↔ 4 mg Ozempic tablets, and 14 mg Rybelsus ↔ 9 mg Ozempic tablets.
Those rules and equivalencies are presented in the label’s switching table and instructions (FDA label (PDF)).
Switching from Ozempic injection to tablets
For patients on 0.5 mg Ozempic injection, the label provides a specific waiting period and then a start dose:
- One week after stopping 0.5 mg injection, start 4 mg or 9 mg Ozempic tablets.
- Or, one week after stopping 0.5 mg injection, start 7 mg or 14 mg Rybelsus tablets.
Again, that’s not a blog’s interpretation; it’s written in the prescribing information (FDA label (PDF)).
Safety: the boxed warning and the predictable traps
Semaglutide tablets carry a boxed warning about thyroid C-cell tumors observed in rodents; the label states it’s unknown whether the risk applies to humans, and it lists contraindications including personal/family history of medullary thyroid carcinoma (MTC) or MEN2 (FDA label (PDF)).
There’s also a practical safety message embedded in the dosing: GI effects are common enough that the label ties the step-up schedule to reducing GI adverse reactions (FDA label (PDF)).
For the peptide-curious reader who is used to seeing “research peptides” marketed as if they were supplements, this is the difference between an FDA-labeled medicine and a story. A label specifies what to do when side effects happen. A story just says you can “titrate as tolerated.”
Why this matters to compounding and the peptide market
When shortages hit GLP-1s, the market doesn’t pause. It improvises. Telehealth brands find ways to route demand. Compounding narratives multiply. People start mixing together half-remembered rules about 503A prescriptions, “copies” of commercially available drugs, and what counts as an “active ingredient.”
Ozempic tablets add a new variable: another FDA-approved semaglutide product that can soak up demand from people who want to avoid injections. If it scales, it could reduce the pressure that pushes patients toward unsupervised supply channels. If it doesn’t scale—if pricing, coverage, or distribution stays tight—expect the same old incentives to remain in place.
For PeptideKnow readers, the actionable point is narrower: don’t confuse “oral semaglutide exists” with “any semaglutide tablet is legitimate.” The FDA-labeled products have named strengths, a specific titration schedule, and explicit switching instructions (FDA label (PDF)). Any vendor selling “semaglutide pills” without that structure is selling a claim, not a drug label.
Where semaglutide sits in the peptide landscape
Semaglutide is part of a larger wave of peptide and peptide-adjacent metabolic therapeutics—some FDA-approved, many still investigational. In the same conversation, you’ll often see people comparing GLP-1 medicines to experimental appetite and metabolism peptides. A few profiles to ground those comparisons:
- Semaglutide (GLP-1 receptor agonist peptide)
- Tirzepatide (dual GIP/GLP-1 agonist; injectable)
- Cagrilintide (amylin analog being studied in combinations)
- Melanotan II (often mentioned in “peptide” circles, but a very different risk/benefit and regulatory context)
- Weight Loss & Metabolic peptides (category overview)
Frequently Asked Questions
Is Ozempic tablets the same as Rybelsus?
Both are oral semaglutide tablets, but the FDA label lists different strengths: Rybelsus (3/7/14 mg) and Ozempic tablets (1.5/4/9 mg) (FDA label (PDF)).
Why does the label say the starting dose isn’t effective?
The prescribing information explicitly states the starting dose is “not effective for glycemic control” and then instructs escalation after 30 days (FDA label (PDF)). The initiation phase functions as a tolerability ramp.
Can I switch from the Ozempic injection to tablets?
The label provides instructions for patients taking 0.5 mg Ozempic injection: discontinue, wait one week, then start oral dosing (either Ozempic tablets 4 mg or 9 mg, or Rybelsus 7 mg or 14 mg) (FDA label (PDF)).
Does this change what’s legal to compound?
This post isn’t legal advice, and compounding legality turns on specific facts. The main point is structural: when more FDA-approved supply is available, the economic incentive to seek alternatives drops. When it isn’t, gray-market narratives expand.
Bottom line
Ozempic tablets bring oral semaglutide into a new branded, FDA-labeled configuration: 1.5 mg → 4 mg → 9 mg with a 30-day initiation phase that the label bluntly calls ineffective for glycemic control (FDA label (PDF)). That may sound like minutiae. It’s not. It’s the difference between medicine and marketing.
Sources (accessed May 10, 2026)
- FDA prescribing information (PDF): RYBELSUS and OZEMPIC tablets (semaglutide)
- Novo Nordisk announcement via PR Newswire (May 1, 2026)
Sources & References
- FDA PCAC Meeting Announcement (July 23-24, 2026)
- PBS: FDA to Weigh Easing Limits on Peptides Favored by RFK Jr.
- BioPharma Dive: FDA Peptides RFK Advisory Committee Restrictions
- RAPS: FDA Considers Adding a Dozen Peptides to Bulk Drug List
- Ars Technica: RFK Jr. Forces FDA to Reconsider 12 Peptides
- ProPublica: Peptide Safety Investigation
- New York Times: Peptide Ban FDA RFK Jr.
- SSRP Institute: FDA Announces Change in Status of 12 Peptides
- CNBC: RFK Jr. Peptides Hims Hers GLP-1
- USA Today: RFK Jr. FDA Peptides Explainer
